10.38

3.89% -0.42

Gh Research Plc (GHRS)

Overview News Price History Option Chain Discussions Forecast

Gh Research Plc stock is traded at $10.38, with a volume of 70,405. It is down -3.89% in the last 24 hours and up +14.07% over the past month. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Previous Close:

$10.80

Open:

$10.97

24h Volume:

70,405

Relative Volume:

0.23

Market Cap:

$706.50M

Revenue:

Net Income/Loss:

$-41.43M

P/E Ratio:

-13.14

EPS:

-0.79

Net Cash Flow:

$-39.97M

1W Performance:

-8.87%

1M Performance:

+14.07%

6M Performance:

+20.56%

1Y Performance:

-13.43%

1-Day Range:

$10.38

$11.22

1-Week Range:

$9.81

$11.50

52-Week Range:

$6.00

$20.50

Gh Research Plc Stock (GHRS) Company Profile

Name

Gh Research Plc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

GHRS's Discussions on Twitter

Compare GHRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GHRS Gh Research Plc	10.38	706.50M	0	-41.43M	-39.97M	-0.79
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Gh Research Plc Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Initiated	Guggenheim	Buy
Mar-07-25	Initiated	RBC Capital Mkts	Outperform
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

Gh Research Plc Stock (GHRS) Latest News

02:44 AM

GH Research (GHRS) Price Target Lowered by Guggenheim | GHRS Sto - GuruFocus

02:44 AM

12:44 PM

GHRS Stock: HC Wainwright & Co. Reiterates Buy Rating | GHRS Sto - GuruFocus

12:44 PM

May 08, 2025

GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025

GHRS Reports Strong Financial Position with Increased Cash Holdi - GuruFocus

May 08, 2025

GH Research Reports Q1 2025 Financial Results Amidst Ongoing Challenges - TipRanks

May 08, 2025

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan

May 08, 2025

May 05, 2025

What Makes GH Research (GHRS) a New Buy Stock - Yahoo Finance

May 05, 2025

May 01, 2025

Where are the Opportunities in (GHRS) - news.stocktradersdaily.com

May 01, 2025

Hims & Hers Health (NYSE:HIMS) Shares Down 8.3% Following Insider Selling - American Banking and Market News

May 01, 2025

Apr 21, 2025

Legal & General Group Plc Sells 18,302 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World

Apr 21, 2025

Apr 18, 2025

What Will GH Research PLC (NASDAQ: GHRS) Be Like In 2025 - Stocksregister

Apr 18, 2025

Apr 16, 2025

Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine

Apr 16, 2025

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga

Mar 20, 2025

Mar 13, 2025

Guggenheim starts GH Research at Buy, sees long-term upside potential - Yahoo Finance

Mar 13, 2025

Guggenheim Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq

Mar 13, 2025

Mar 11, 2025